Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the biotechnology company’s stock, valued at approximately $276,000.
A number of other institutional investors have also recently made changes to their positions in the business. Krilogy Financial LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $287,000. JPMorgan Chase & Co. increased its position in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after acquiring an additional 45,381 shares during the period. Virtu Financial LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at $458,000. Barclays PLC raised its stake in shares of Capricor Therapeutics by 106.6% in the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock valued at $552,000 after acquiring an additional 18,724 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in Capricor Therapeutics in the third quarter valued at $938,000. Institutional investors and hedge funds own 21.68% of the company’s stock.
Capricor Therapeutics Trading Up 6.0 %
Shares of NASDAQ:CAPR opened at $14.90 on Thursday. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40. The company’s fifty day moving average price is $15.22 and its 200 day moving average price is $11.75.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Capricor Therapeutics
Capricor Therapeutics Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than Capricor Therapeutics
- Stock Sentiment Analysis: How it Works
- Oracle Announces Game-Changing News for the AI Industry
- Trading Stocks: RSI and Why it’s Useful
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Calculate Inflation Rate
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.